Soluble ST2 Is a Sensitive and Specific Biomarker for Fulminant Myocarditis.
Jin Wang,Mengying He,Huihui Li,Yanghui Chen,Xiang Nie,Yuanyuan Cai,Rong Xie,Lijuan Li,Peng Chen,Yang Sun,Chenze Li,Ting Yu,Houjuan Zuo,Guanglin Cui,Kun Miao,Chunxia Zhao,Jiangang Jiang,Bettina Heidecker,Olga Barnett,Alan Maisel,Chen Chen,Dao Wen Wang
DOI: https://doi.org/10.1161/jaha.121.024417
IF: 6.106
2022-04-06
Journal of the American Heart Association
Abstract:Background The aim of the study was to identify biomarkers that can facilitate early diagnosis and treatment of fulminant myocarditis (FM) in order to reduce mortality. Methods and Results First, the expression profiles of circulating cytokines were determined in the plasma samples from 4 patients with FM and 4 controls using human cytokine arrays. The results showed that 39 cytokines from patients with FM were changed at admission. Among them, 8 cytokines returned to normal levels at discharge, including soluble ST2 (sST2), which showed the most marked dynamic changes from disease onset to resolution. Then, in a cohort of 76 patients with FM, 57 patients with acute hemodynamic dysfunction attributable to other causes, and 56 patients with non‐FM, receiver operating characteristic curve analyses suggested that plasma sST2 level was able to differentiate FM from non‐FM or other FM‐unrelated acute heart failure more robustly N‐terminal pro‐B‐type natriuretic peptide or cardiac troponin I. Moreover, longitudinal analysis of plasma sST2 was performed in 10 patients with FM during hospitalization and 16 patients with FM during follow‐up. Finally, the diagnostic value was validated in an additional 26 patients with acute onset of unstable hemodynamics. The cutoff value of plasma sST2 for optimal diagnosis of FM was established at 58.39 ng/mL, where a sensitivity of 85.7% and specificity of 94.7% were achieved. Conclusions Elevated sST2 level was associated with mechanical stress or inflammation. Especially, sST2 might be used as a potential biomarker for the rapid diagnosis of FM, which was characterized by strong mechanical stretch stimulation and severe inflammatory response. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT03268642. Nonstandard Abbreviations and Acronyms cTnI cardiac troponin I FM fulminant myocarditis NFM nonfulminant myocarditis sST2 soluble ST2 Clinical Perspective What Is New? In the current study, we found a significant induction of a broad spectrum of inflammatory cytokines in patients' plasma at the onset of fulminant myocarditis, supporting the presence of so‐called inflammatory storm as a part of the pathogenic features of the disease. What Are the Clinical Implications? The induction and normalization of plasma soluble ST2 were significantly and specifically correlated with the onset and clinical improvement of fulminant myocarditis, implicating its potential diagnosis role in the disease. Myocarditis is a rare disease, with a prevalence of ≈22 per 100 000 people. 1 Acute myocarditis is generally considered a mild and self‐limited condition caused by infection, autoimmune disorders, poisoning, or toxic drug effects, although some cases can progress to chronic heart failure (HF). 2 , 3 , 4 While multiple pharmacological drugs have been associated with myocarditis, temporal trends and overall mortality have not been reported. Systematic analysis of drug‐associated myocarditis reported in the World Health Organization pharmacovigilance database promoted trials on the use of steroids and interleukin (IL) 1β inhibitors, which might change therapeutic perspectives (ClinicalTrials.gov Identifier: NCT05150704 and NCT03018834). 5 Fulminant myocarditis (FM), however, is the most severe type of myocarditis characterized by its sudden occurrence and rapid deterioration. 6 Patients with FM quickly develop hemodynamic dysfunction and require immediate mechanical circulatory support. Moreover, respiratory, liver, or kidney failure may occur simultaneously. 7 , 8 In a study based on an international multicenter registry, Ammirati et al 9 found that patients with FM had significantly higher rates of cardiac death and heart transplantation than those with non‐FM (NFM) at both 60‐day (28.0% versus 1.8%) and 7‐year (47.7% versus 10.4%) follow‐up. Therefore, developing an effective diagnostic and treatment regimen for FM remains to be a significant clinic challenge with major unmet needs. It is emphasized by both the American -Abstract Truncated-
cardiac & cardiovascular systems